• DOI:10.1007/s10067-019-04775-z
Corpus ID: 202573838

Increased circulating CXCL13 levels in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis

@article{Bao2019IncreasedCC,
  title={Increased circulating CXCL13 levels in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis},
  author={Yu-Qing Bao and J. Wang and Ziwei Dai and Yan-Mei Mao and J. Wu and H. Guo and Yuan-Rui Xia and D. Ye},
  journal={Clinical Rheumatology},
  year={2019},
  volume={39},
  pages={281-290}
}

Yu-Qing Bao, J. Wang, +5 authors D. Ye

Published 2019

Medicine

Clinical Rheumatology

Objectives CXC ligand 13 (CXCL13) is known as B cell chemotactic factor (BLC), promoting the migration of B lymphocytes by communicating with its receptor CXCR5, which can be regarded as part of pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). This meta-analysis was to evaluate the circulating CXCL13 levels in SLE and RA. Methods All articles were respectively gathered from PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI) (by the end of… CONTINUE READING

View on Springer

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed